Vaccine efficacy against all episodes of clinical and severe malaria in infants aged 6–12 wk at enrollment.

1Event rate for clinical malaria; affected rate (percent) for severe malaria and hospitalization.2For clinical malaria: p-value from negative binomial regression. For severe malaria, malaria hospitalization, and all-cause hospitalization: p-value from two-sided Fisher's exact test.3Clinical malaria primary case definition: illness in a child brought to a study facility with a measured temperature of ≥37.5°C and P. falciparum asexual parasitemia at a density of >5,000 parasites/mm3 or a case of malaria meeting the primary case definition of severe malaria.4Clinical malaria secondary case definition: illness in a child brought to a study facility with a measured temperature of ≥37.5°C or reported fever within the last 24 h and P. falciparum asexual parasitemia at a density of >0 parasites/mm3.5Severe malaria primary case definition: P. falciparum asexual parasitemia at a density of >5,000 parasites/mm3 with one or more markers of disease severity and without diagnosis of a coexisting illness. Markers of severe disease were prostration, respiratory distress, a Blantyre coma score of ≤2 (on a scale of 0 to 5, with higher scores indicating a higher level of consciousness), two or more observed or reported seizures, hypoglycemia, acidosis, elevated lactate level, or hemoglobin level of 6Malaria hospitalization case definition: a medical hospitalization with confirmed P. falciparum asexual parasitemia at a density of >5,000 parasites/mm3.7All-cause hospitalization primary case definition: a medical hospitalization of any cause, excluding planned admissions for medical investigation/care or elective surgery and admissions for trauma.